查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1570841

抗风湿药物市场：依产品类型、给药途径、药物类别、疾病类型 - 全球预测 2025-2030

Anti-Rheumatics Market by Product Type (Biologics, Non-Biologics), Route Of Administration (Injectable, Oral, Topical), Drug Class, Disease Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗风湿药物市值为606.7亿美元，预计2024年将达632.8亿美元，复合年增长率为5.12%，到2030年将达到860.9亿美元。

抗风湿药物市场包括旨在治疗类风湿性关节炎和其他导致慢性发炎和关节疼痛的相关自体免疫疾病的药物和治疗方法。由于世界老化和疾病流行，对有效治疗的持续需求，这个市场变得极为重要。抗风湿药物对于缓解症状、改善患者的生活品质和减缓疾病进展至关重要。最终使用者主要是医院、诊所和专科中心。市场成长的推动因素包括自体免疫疾病意识的提高、生技药品和生物仿製药的进步以及新兴地区医疗保健服务的扩大。此外，个人化医疗和标靶治疗代表着巨大的商机，新型生技药品和口服 JAK 抑制剂因具有改变治疗模式的潜力而备受关注。

主要市场统计
基准年[2023] 606.7亿美元
预测年份 [2024] 632.8亿美元
预测年份 [2030] 860.9亿美元
复合年增长率（%） 5.12%

然而，挑战依然存在，包括严格的监管要求、高昂的药物开发成本以及给定价策略带来压力的学名药的出现。由于成本相关的限制，市场也面临患者获得新治疗方法的机会有限。製药公司与研究机构在研发和行销方面的策略联盟和合作可以改善产品供应和市场渗透。此外，创新领域的开拓时机已经成熟，包括开发新型小分子、更加关注个人化治疗的生物标誌物，以及使用人工智慧来缩短时间并提高功效。

儘管面临竞争压力，透过提高安全性和减少副作用来关注产品差异化可以增加消费者的偏好。建议的策略是保持强大的管道并进行持续的市场监测，以了解不断变化的人口和流行病学趋势。市场的动态性质凸显了有效的打入市场策略的重要性，以利用未满足的需求，以及对医疗基础设施不断发展和法律体制不断完善的新兴经济体进行投资。透过解决这些多方面的因素，公司可以有效地定位自己以实现持续成长。

市场动态：揭示快速发展的抗风湿药物市场的关键市场洞察

供需的动态交互作用正在改变抗风湿药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业减轻政治、地理、技术、社会和经济领域的风险，以及消费行为及其对製造成本的影响及其对采购趋势的影响。

波特五力：驾驭抗风湿药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗风湿药物市场的外部影响

外部宏观环境因素在塑造抗风湿药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解抗风湿药市场竞争状况

抗风湿药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵抗风湿药物市场供应商绩效评估

FPNV定位矩阵是评估抗风湿药市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘抗风湿药物市场的成功之路

抗风湿药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告提供了涵盖主要焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾。

2. 市场开拓：辨识新兴市场的成长机会，评估现有产业的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检视市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 创新的抗风湿药物给药系统可提高患者依从性和治疗结果
      • 政府措施和有利的报销政策推动市场成长
      • 扩大新抗风湿疗法的临床试验与研发活动
      • 改善患者获得卫生服务的机会并改善抗风湿药物的采用
    • 抑制因素
      • 先进的生物治疗方法在发展中地区受到限制，影响了治疗的可近性和公平性。
      • 患者对规定治疗方案的依从性差会导致治疗结果不佳并增加疾病负担
    • 机会
      • 老年人类风湿性关节炎盛行率的增加推动了抗风湿药物的需求
      • 加大抗风湿新药研发投入
      • 提高患者和医疗保健专业人员对类风湿性关节炎早期诊断和治疗的认识
    • 任务
      • 需要更好的诊断工具和生物标记来改善类风湿性关节炎的早期检测和治疗结果
      • 管理与长期使用抗风湿药物相关的併发症和副作用的问题
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章抗风湿药市场：依产品类型

  • 介绍
  • 生技药品
    • IL-1抑制剂
    • IL-6抑制剂
    • JAK抑制剂
    • 肿瘤坏死因子抑制剂
  • 非生技药品
    • 皮质类固醇
    • DMARD（抗逆转录病毒药物）
    • NSAIDs

第七章 抗风湿药物市场：依给药途径

  • 介绍
  • 注射
  • 口服
  • 局部的

第八章抗风湿药物市场：依药物类别

  • 介绍
  • 缓解疾病抗风湿药物 (DMARD)
    • 生物DMARD
      • 生物相似药DMARD
    • 合成DMARD
      • 传统合成 DMARD
      • 标靶合成DMARD
  • 非类固醇消炎剂(NSAID)

第九章抗风湿药物市场：依疾病类型

  • 介绍
  • 僵直性脊椎炎
  • 骨关节炎
  • 干癣性关节炎
  • 类风湿性关节炎

第十章 北美及南美洲抗风湿药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太抗风湿药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲抗风湿药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0147

The Anti-Rheumatics Market was valued at USD 60.67 billion in 2023, expected to reach USD 63.28 billion in 2024, and is projected to grow at a CAGR of 5.12%, to USD 86.09 billion by 2030.

The anti-rheumatics market encompasses a range of pharmaceuticals and therapies designed to treat rheumatoid arthritis and other related autoimmune conditions, which cause chronic inflammation and joint pain. This market is vital due to the persistent demand for effective treatments caused by an aging global population and increasing disease prevalence. Anti-rheumatics are critical in mitigating symptoms, improving patient quality of life, and slowing disease progression. End-users primarily include hospitals, clinics, and specialty centers. Market growth is driven by factors such as rising awareness of autoimmune disorders, advancements in biologics and biosimilars, and expanded healthcare access in emerging regions. Additionally, personalized medicine and targeted therapies represent significant opportunities, with new biologics and oral JAK inhibitors receiving attention for their potential to revolutionize treatment paradigms.

KEY MARKET STATISTICS
Base Year [2023] USD 60.67 billion
Estimated Year [2024] USD 63.28 billion
Forecast Year [2030] USD 86.09 billion
CAGR (%) 5.12%

However, challenges persist, like stringent regulatory requirements, high drug development costs, and the emergence of generic alternatives, which put pressure on pricing strategies. The market also faces limitations in terms of patient access to newer therapies due to cost-related constraints. Strategic partnerships and collaborations for research, development, and distribution among pharmaceutical companies and research institutes can lead to improved product offerings and market penetration. Furthermore, innovation areas ripe for exploration include the development of novel small molecules, increased focus on biomarkers for personalized treatment, and leveraging AI for drug discovery processes to reduce time and improve efficacy.

Despite competitive pressures, focusing on differentiating products through improved safety profiles and reduced side effects can drive consumer preference. Maintaining robust pipelines and engaging in continuous market surveillance to identify shifting demographic and epidemiological trends are recommended strategies. The market's dynamic nature highlights the importance of effective market entry strategies to capitalize on unmet needs, alongside investing in developing economies where healthcare infrastructure is growing and legal frameworks are improving. By addressing these multifaceted factors, companies can effectively position themselves for sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Rheumatics Market

The Anti-Rheumatics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Innovative drug delivery systems enhancing patient compliance and therapeutic outcomes in anti-rheumatics
    • Government initiatives and favorable reimbursement policies driving market growth
    • Expansion of clinical trials and R&D activities for novel anti-rheumatic treatments
    • Increased patient access to healthcare services improving the adoption of anti-rheumatic medications
  • Market Restraints
    • Limited availability of advanced biological therapies in underdeveloped regions affecting treatment access and equity
    • Low patient adherence to prescribed treatment regimens leading to suboptimal therapeutic outcomes and increased disease burden
  • Market Opportunities
    • Increasing prevalence of rheumatoid arthritis among geriatric population driving demand for anti-rheumatics
    • Growing investment in research and development initiatives for novel anti-rheumatic drugs
    • Rising awareness among patients and healthcare providers about early diagnosis and treatment of rheumatoid arthritis
  • Market Challenges
    • The need for better diagnostic tools and biomarkers to improve early detection and treatment outcomes in rheumatoid arthritis
    • The challenge of managing comorbidities and side effects associated with long-term use of anti-rheumatic medications

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Rheumatics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Rheumatics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Rheumatics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Rheumatics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Rheumatics Market

A detailed market share analysis in the Anti-Rheumatics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Rheumatics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Rheumatics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Rheumatics Market

A strategic analysis of the Anti-Rheumatics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Rheumatics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline plc, ILTOO Pharma, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., UCB S.A., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Anti-Rheumatics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Biologics and Non-Biologics. The Biologics is further studied across IL-1 Inhibitors, IL-6 Inhibitors, JAK Inhibitors, and TNF Inhibitors. The Non-Biologics is further studied across Corticosteroids, DMARDs, and NSAIDs.
  • Based on Route Of Administration, market is studied across Injectable, Oral, and Topical.
  • Based on Drug Class, market is studied across Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The Disease-Modifying Anti-Rheumatic Drugs (DMARDs) is further studied across Biologic DMARDs and Synthetic DMARDs. The Biologic DMARDs is further studied across Biosimilar DMARDs. The Synthetic DMARDs is further studied across Conventional Synthetic DMARDs and Targeted Synthetic DMARDs.
  • Based on Disease Type, market is studied across Ankylosing Spondylitis, Osteoarthritis, Psoriatic Arthritis, and Rheumatoid Arthritis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Innovative drug delivery systems enhancing patient compliance and therapeutic outcomes in anti-rheumatics
      • 5.1.1.2. Government initiatives and favorable reimbursement policies driving market growth
      • 5.1.1.3. Expansion of clinical trials and R&D activities for novel anti-rheumatic treatments
      • 5.1.1.4. Increased patient access to healthcare services improving the adoption of anti-rheumatic medications
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability of advanced biological therapies in underdeveloped regions affecting treatment access and equity
      • 5.1.2.2. Low patient adherence to prescribed treatment regimens leading to suboptimal therapeutic outcomes and increased disease burden
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing prevalence of rheumatoid arthritis among geriatric population driving demand for anti-rheumatics
      • 5.1.3.2. Growing investment in research and development initiatives for novel anti-rheumatic drugs
      • 5.1.3.3. Rising awareness among patients and healthcare providers about early diagnosis and treatment of rheumatoid arthritis
    • 5.1.4. Challenges
      • 5.1.4.1. The need for better diagnostic tools and biomarkers to improve early detection and treatment outcomes in rheumatoid arthritis
      • 5.1.4.2. The challenge of managing comorbidities and side effects associated with long-term use of anti-rheumatic medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Rheumatics Market, by Product Type

  • 6.1. Introduction
  • 6.2. Biologics
    • 6.2.1. IL-1 Inhibitors
    • 6.2.2. IL-6 Inhibitors
    • 6.2.3. JAK Inhibitors
    • 6.2.4. TNF Inhibitors
  • 6.3. Non-Biologics
    • 6.3.1. Corticosteroids
    • 6.3.2. DMARDs
    • 6.3.3. NSAIDs

7. Anti-Rheumatics Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral
  • 7.4. Topical

8. Anti-Rheumatics Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    • 8.2.1. Biologic DMARDs
      • 8.2.1.1. Biosimilar DMARDs
    • 8.2.2. Synthetic DMARDs
      • 8.2.2.1. Conventional Synthetic DMARDs
      • 8.2.2.2. Targeted Synthetic DMARDs
  • 8.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

9. Anti-Rheumatics Market, by Disease Type

  • 9.1. Introduction
  • 9.2. Ankylosing Spondylitis
  • 9.3. Osteoarthritis
  • 9.4. Psoriatic Arthritis
  • 9.5. Rheumatoid Arthritis

10. Americas Anti-Rheumatics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Anti-Rheumatics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Anti-Rheumatics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca plc
  • 4. Biogen Inc.
  • 5. Boehringer Ingelheim GmbH
  • 6. Bristol-Myers Squibb Company
  • 7. Eli Lilly and Company
  • 8. Galapagos NV
  • 9. Gilead Sciences, Inc.
  • 10. GlaxoSmithKline plc
  • 11. ILTOO Pharma
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Regeneron Pharmaceuticals, Inc.
  • 17. Roche Holding AG
  • 18. Sanofi S.A.
  • 19. UCB S.A.
  • 20. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. ANTI-RHEUMATICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-RHEUMATICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-RHEUMATICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-RHEUMATICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOSIMILAR DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL SYNTHETIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 73. CANADA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 120. CHINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 129. INDIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 283. ITALY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. POLAND ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. POLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 319. POLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. QATAR ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. QATAR ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 328. QATAR ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 331. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 333. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 334. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 335. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 336. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 340. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 341. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 342. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 343. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 344. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 345. SAUDI ARABIA ANTI-RHEUMATICS